SEHK:9995Biotechs
RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative
Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, both supported by positive Phase 2 and Phase 3 clinical data.
These decisions expand telitacicept to five approved autoimmune indications in China, underscoring the clinical breadth of RemeGen’s first-in-class BLyS/APRIL dual-target biologic.
We’ll now examine how this broadened telitacicept...